Skip to main content
Top

Biotherapy

Issue 4/1998

Content (9 Articles)

Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide

Li Li, Takashi Okino, Norimichi Kan, Seiji Yamasaki, You Ichinose, Tomoharu Sugie, Shunji Kanaoka, Masayuki Imamura

The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients

Takusaburo Ebina, Yoshiaki Fujimiya, Tomohiro Yamaguchi, Naoko Ogama, Hiroko Sasaki, Noriko Isono, Youichi Suzuki, Ryuichi Katakura, Kazuya Tanaka, Kinya Nagata, Shoichi Takano, Keiji Tamura, Kazuko Uno, Tsunataro Kishida

Levamisole and Interleukin-2 for advanced malignancy

Randall F. Holcombe, Ailing Li, Ruby M. Stewart

Contribution of cytokines on the suppression of lung metastasis

Yoko Ishihara, Hiroko Iijima, Kenichi Matsunaga

EIevated serum level of Thioredoxin in patients with Hepatocellular Carcinoma

Kunihisa Miyazaki, Noriko Noda, Shuichi Okada, Yoshiaki Hagiwara, Michio Miyata, Ikunosuke Sakurabayashi, Naohito Yamaguchi, Takashi Sugimura, Masaaki Terada, Hiro Wakasugi

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources

Sandro Eridani, Umberto Mazza, Paolo Massaro, Maria Luisa La Targia, Anna Teresa Maiolo, Andrea Mosca

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine